Evidence map›Paper›PMID 38495493›Full record

ArticleJournal of Cancer2024

Lasiokaurin Regulates PLK1 to Induce Breast Cancer Cell G2/M Phase Block and Apoptosis.

Zhengrui Liu, Jia Wang, Siman Xie, Benteng Zhang, Yan Yuan, Huaizi Fu, Hongyun Hao, Li Sun, Shengtao Yuan, Jian Ding and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Zhengrui LiuJiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, China.
Jia WangJiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, China.
Siman XieJiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, China.
Benteng ZhangJiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, China.
Yan YuanJiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, China.
Huaizi FuJiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, China.
Hongyun HaoJiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, China.
Li SunJiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, China.
Shengtao YuanJiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, China.
Jian DingChinese Academy of Sciences Shanghai Institute of Materia Medica, Shanghai, China.
Hong YuDepartment of Pathology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, Jiangsu, China.
Mei YangJiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, China.
China Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

apoptosisbreast cancerG2/M phase blockLasiokaurinPLK1

Identifiers

PMID38495493
PMCPMC10937283
OpenAlexW4392826796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.